PDE-5 Inhibition and Sexual Response: Pharmacological Mechanisms and Clinical Outcomes
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Phosphodiesterase type-5 (PDE-5) inhibitors are a new class of vasoactive drugs that have been developed for treatment of erectile dysfunction (ED). The mechanism of action involves active inhibition of the PDE-5 enzyme and resulting increase in cyclic guanosine monophosphate (cGMP) and smooth muscle relaxation in the penis. Sildenafil citrate (Viagra) is a potent and selective PDE-5 inhibitor, which is the first drug in this class to be approved for treatment of ED. More than 10 million men worldwide have been treated with this drug. Sildenafil has been shown to be generally effective in the treatment of ED, although the degree of efficacy varies according to the etiology and severity of the disorder. The drug is well tolerated, with relatively few contraindications (e.g., nitrates) and safety risks. The cardiovascular effects of sildenafil, in particular, have been extensively investigated. The results of recent studies suggest that sildenafil may have an additional role in the treatment of other male and female sexual disorders, such as premature ejaculation and female sexual arousal disorder, although results to date are inconclusive. Two additional agents in this class (tadalafil [Cialis], vardenafil [Levitra]) have been developed recently and are under regulatory review. Tadalafil is a long-acting PDE-5 inhibitor, which is effective for up to 36 hr in the majority of men. Vardenafil has a similar duration of action to sildenafil, but is more potent and selective biochemically. Both drugs appear to be generally safe and well tolerated, with a similar side-effect profile to sildenafil. There are no controlled comparison studies to date. Despite the overall effectiveness of PDE-5 inhibitors in the treatment of ED, significant psychological and interpersonal issues need to be addressed in their clinical use. The potential impact on societal attitudes toward sexuality and sexual dysfunction also warrants consideration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., & Mishra, A. (1997) · Urology · doi:10.1016/s0090-4295(97)00238-0 · Cited by 5,849
Self-citationSexual Dysfunction in the United States: Prevalence and Predictors
Laumann, E. O., Paik, A., & Rosen, R. C. (1999) · JAMA · doi:10.1001/jama.281.6.537 · Cited by 5,119
Self-citationImpotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study
Feldman, H. A., Goldstein, I., Hatzichristou, D. G., Krane, R. J., & McKinlay, J. B. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)34871-1 · Cited by 5,074
Oral Sildenafil in the Treatment of Erectile Dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., & Wicker, P. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382001 · Cited by 2,120
Self-citationAndersson, K. E., & Wagner, G. (1995) · Physiological Reviews · doi:10.1152/physrev.1995.75.1.191 · Cited by 1,119
(1999) · doi:10.1016/s0090-4295(99)00099-0 · Cited by 1,051
Self-citationTreatment of Men with Erectile Dysfunction with Transurethral Alprostadil
Padma-Nathan, H., Hellstrom, W. J. G., Kaiser, F. E., Labasky, R. F., Lue, T. F., Nolten, W. E., Norwood, P. C., Peterson, C. A., Shabsigh, R., Tam, P. Y., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701023360101 · Cited by 574
Sildenafil-associated nonarteritic anterior ischemic optic neuropathy
Pomeranz, H. D., Smith, K. H., Hart, W. M., & Egan, R. A. (2002) · Ophthalmology · doi:10.1016/s0161-6420(01)00976-9 · Cited by 173
The Medicalization of Female Sexual Dysfunction: The Need for Caution
Bancroft, J. (2002) · Archives of Sexual Behavior · doi:10.1023/a:1019800426980 · Cited by 146 · cited 1×
“On the other hand, some authors have raised concerns about potential risks associated with the “medicalization” of male sexuality and the increasing role of the pharmaceutical industry in this area (Bancroft, 2002; Tiefer, 2000).”
BackgroundQuality of Partnership in Patients with Erectile Dysfunction after Sildenafil Treatment
Müller, M. J., Ruof, J., Graf-Morgenstern, M., Porst, H., & Benkert, O. (2001) · Pharmacopsychiatry · doi:10.1055/s-2001-14277 · Cited by 66
Bischoff, E., & Schneider, K. (2001) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900703 · Cited by 52
Cited by
Hull, E. M., & Rodríguez-Manzo, G. (2009) · Hormones, Brain and Behavior · doi:10.1016/b978-008088783-8.00001-2 · Cited by 374
Ammirante, M., Shalapour, S., Kang, Y., Jamieson, C. A. M., & Karin, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416498111 · Cited by 206
Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms?
Chivers, M. L., & Rosen, R. C. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01599.x · Cited by 100
Self-citationRosen, R., Janssen, E., Wiegel, M., Bancroft, J., Althof, S., Wincze, J., Segraves, R. T., & Barlow, D. (2006) · Journal of Sex & Marital Therapy · doi:10.1080/00926230600575314 · Cited by 43
“Department of Psychology, Case School of Medicine, Cleveland, Ohio, USA”
BackgroundInfluentialSelf-citationMcCabe, M., & Price, E. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.00885.x · Cited by 35
Metadata
- Authors
- Rosen, R. C., & McKenna, K. E.
- Venue
- Annual Review of Sex Research
- Publisher
- Informa UK Limited
- Published
- 2002-03
- Volume
- 13
- Issue
- 1
- Pages
- 36-88
- ISSN
- 1053-2528 (ISSN-L)
- OpenAlex
- W1566391955
- Cited by
- 84
- References
- 11
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.